Safety of pediatric HIV elimination: the growing population of HIV- and antiretroviral-exposed but uninfected infants.
Lynne Mofenson and Heather Watts discuss the context and implications of the study by J. Sibuide and colleagues, which provides a detailed analysis of birth defects in infants with in utero antiretroviral drug exposure in the French Perinatal Cohort. Please see later in the article for the Editors' Summary.
Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America.
Lynne M
LM
Mofenson
Office of the Global AIDS Coordinator, US Department of State, Washington (D.C.), United States of America.
D Heather
DH
Watts
D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000013:Congenital Abnormalities / Q000209:etiology*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006330:Heart Defects, Congenital / Q000139:chemically induced*; D006801:Humans; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000453:epidemiology*
D019380:Anti-HIV Agents